Dukes Iain D. — SEC Form 4 filings
SEC reporting owner CIK 1681955. 14 Form 4 filings on record with FilingPulse; latest filed 2026-07-14.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-02-14 to 2026-07-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 32,000 shares, $292,800 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: purchase of 32,000 shares @ $9.15 ($292,800) in IOVANCE BIOTHERAPEUTICS, INC., filed 2024-02-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Director | 5 | 1 leg · 32,000 sh · $292,800 | — | 4 |
| Traws Pharma, Inc. (TRAW) | Chief Executive Officer, Director | 6 | — | — | 12 |
| Theseus Pharmaceuticals, Inc. (THRX) | Director | 1 | — | — | 5 |
| Ikena Oncology, Inc. (IKNA) | Director | 1 | — | — | 1 |
| Lomond Therapeutics Holdings, Inc. | CEO and Chairman, Director | 1 | — | — | 1 |
Form 4 filings — Dukes Iain D.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-14 | 4 | Traws Pharma, Inc. (TRAW) | Grant/award (A): 274,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 180,632 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Traws Pharma, Inc. (TRAW) | Grant/award (A): 231,336 (derivative) @ $0 | EDGAR |
| 2025-12-16 | 4 | Traws Pharma, Inc. (TRAW) | Grant/award (A): 36,943 @ $0 · Grant/award (A): 147,771 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Traws Pharma, Inc. (TRAW) | Grant/award (A): 64,839 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 135,092 (derivative) @ $0 | EDGAR |
| 2024-11-05 | 4 | Lomond Therapeutics Holdings, Inc. | Grant/award (A): 2,096,667 (derivative) @ $0 | EDGAR |
| 2024-08-07 | 4/A | Traws Pharma, Inc. (TRAW) | Grant/award (A): 67,500 | EDGAR |
| 2024-06-13 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 98,607 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Ikena Oncology, Inc. (IKNA) | Grant/award (A): 17,520 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Traws Pharma, Inc. (TRAW) | Grant/award (A): 66,687 · Grant/award (A): 67,550 · Grant/award (A): 1,645,100 · Grant/award (A): 3,802,890 (derivative) · Grant/award (A): 194.62 (derivative) · Grant/award (A): 4,801.11 (derivative) | EDGAR |
| 2024-03-05 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Purchase (P): 32,000 @ $9.15 | EDGAR |
| 2024-02-14 | 4 | Theseus Pharmaceuticals, Inc. (THRX) | Code (U): 388,324 · Disposition to issuer (D): 3,250 (derivative) · Disposition to issuer (D): 344,344 (derivative) · Disposition to issuer (D): 36,066 (derivative) · Disposition to issuer (D): 61,549 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1681955 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →